BRPI0606301A2 - processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos - Google Patents

processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos

Info

Publication number
BRPI0606301A2
BRPI0606301A2 BRPI0606301-2A BRPI0606301A BRPI0606301A2 BR PI0606301 A2 BRPI0606301 A2 BR PI0606301A2 BR PI0606301 A BRPI0606301 A BR PI0606301A BR PI0606301 A2 BRPI0606301 A2 BR PI0606301A2
Authority
BR
Brazil
Prior art keywords
mixture
polypeptide
salts
pharmaceutical composition
making
Prior art date
Application number
BRPI0606301-2A
Other languages
English (en)
Inventor
Ben-Zion Dolitzky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0606301A2 publication Critical patent/BRPI0606301A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PROCESSO PARA FABRICAR UMA MISTURA DE SAIS DE ACETATO DE POLIPEPTìDEOS, PROCESSO PARA FABRICAR UMA MISTURA DE SAIS DE POLIPETìDEOS DE TRIFLUOROACETILA NãO PROTEGIDOS, MISTURA DE SAIS DE ACETATO DE POLIPEPTìDEOS, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA, E, MISTURA DE POLIPEPTìDEOS DE TRIFLUOROACETILA PROTEGIDOS. A presente invenção diz respeito a um processo melhorado para fabricar uma mistura de sais de acetatos de polipeptídeos, cada um dos quais consistindo de ácido glutâmico, alanina, tirosina e usina, para o uso no tratamento de esclerose múltipla.
BRPI0606301-2A 2005-02-02 2006-01-20 processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos BRPI0606301A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64944205P 2005-02-02 2005-02-02
PCT/US2006/002351 WO2006083608A1 (en) 2005-02-02 2006-01-20 Process for producing polypeptide mixtures using hydrogenolysis

Publications (1)

Publication Number Publication Date
BRPI0606301A2 true BRPI0606301A2 (pt) 2009-07-07

Family

ID=36777558

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606301-2A BRPI0606301A2 (pt) 2005-02-02 2006-01-20 processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos

Country Status (16)

Country Link
US (1) US20060172942A1 (pt)
EP (1) EP1838326A4 (pt)
JP (1) JP2008528589A (pt)
KR (1) KR20070108388A (pt)
CN (1) CN101111252A (pt)
AU (1) AU2006211510B8 (pt)
BR (1) BRPI0606301A2 (pt)
CA (1) CA2594022A1 (pt)
IL (1) IL183610A0 (pt)
MX (1) MX2007009296A (pt)
NO (1) NO20074374L (pt)
NZ (1) NZ556156A (pt)
RU (1) RU2419638C2 (pt)
UA (1) UA93669C2 (pt)
WO (1) WO2006083608A1 (pt)
ZA (1) ZA200705874B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
CA2469393C (en) * 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US7495072B2 (en) * 2004-09-09 2009-02-24 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
US20080261894A1 (en) * 2005-02-17 2008-10-23 Rivka Kreitman Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
EP2173766A1 (en) * 2007-07-31 2010-04-14 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
US20090149541A1 (en) * 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
EP2277050B2 (en) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US8212002B2 (en) * 2008-08-07 2012-07-03 Scinopharm Taiwan Ltd Synthesis of glatiramer acetate
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
WO2010115175A1 (en) 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
DK2949335T3 (en) 2009-08-20 2017-07-31 Yeda Res & Dev LOW FREQUENT GLATIRAMER ACETATE THERAPY
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US9109006B2 (en) * 2010-07-29 2015-08-18 Santhanakrishnan Srinivasan Glatiramer acetate molecular weight markers
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
ES2654291T3 (es) 2011-02-14 2018-02-13 Usv Private Limited Copolímero-1, proceso para la preparación y sus métodos de análisis
GB2478837A (en) * 2011-03-14 2011-09-21 Cipla Ltd Preparation of glatiramer
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
EP2906719A4 (en) 2012-10-10 2016-11-09 Teva Pharma PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN104610436A (zh) * 2015-02-03 2015-05-13 郑州大明药物科技有限公司 一种醋酸格拉替雷的制备方法
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) * 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS5828867B2 (ja) * 1979-07-13 1983-06-18 財団法人 微生物化学研埋会 新テトラペプチド誘導体類
US4935405A (en) * 1986-10-31 1990-06-19 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
MX9301789A (es) * 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
JP3622187B2 (ja) * 1995-09-26 2005-02-23 Ｊｓｒ株式会社 ポリ−α−アミノ酸粒子の製造方法
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) * 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CA2469393C (en) * 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
CA2411786C (en) * 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
EP1565486A2 (en) * 2002-11-13 2005-08-24 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
EP1592384B1 (en) * 2003-01-21 2012-10-31 Yeda Research And Development Co., Ltd. Cop 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
SI1638589T1 (sl) * 2003-05-14 2014-07-31 Teva Pharmaceutical Industries Ltd. Kombinirana terapija z glatiramer acetatom in mitoksantronom za zdravljenje multiple skleroze
US20050170004A1 (en) * 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
WO2005048435A1 (de) * 2003-11-13 2005-05-26 Sew-Eurodrive Gmbh & Co. Kg Kompaktantrieb
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
US7495072B2 (en) * 2004-09-09 2009-02-24 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
NZ560660A (en) * 2005-02-23 2010-11-26 Teva Pharma Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007030573A2 (en) * 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
AU2006316585B2 (en) * 2005-11-17 2012-09-20 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20090149541A1 (en) * 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis

Also Published As

Publication number Publication date
AU2006211510B8 (en) 2011-04-21
RU2007132889A (ru) 2009-03-10
MX2007009296A (es) 2007-09-21
NZ556156A (en) 2010-03-26
AU2006211510A1 (en) 2006-08-10
JP2008528589A (ja) 2008-07-31
EP1838326A1 (en) 2007-10-03
IL183610A0 (en) 2008-04-13
EP1838326A4 (en) 2009-09-30
UA93669C2 (ru) 2011-03-10
CA2594022A1 (en) 2006-08-10
WO2006083608A1 (en) 2006-08-10
CN101111252A (zh) 2008-01-23
KR20070108388A (ko) 2007-11-09
RU2419638C2 (ru) 2011-05-27
NO20074374L (no) 2007-10-24
ZA200705874B (en) 2009-04-29
US20060172942A1 (en) 2006-08-03
AU2006211510B2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
BRPI0606301A2 (pt) processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos
BRPI0515033A8 (pt) processo para a obtenção de uma mistura de polipetídeos de trifluoroacetila, mistura de polipeptídeos de trifluoroacetila, e, processos para a obtenção de uma composição farmacêutica, e para a produção de acetato de glatirâmetro
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
HRP20171694T1 (hr) Novi pripravci i postupci
EA202090053A2 (ru) Способы и композиции для лечения неэффективного эритропоэза
EP2455460A3 (en) Lipase variants for pharmaceutical use
NZ591497A (en) A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
IL184771A (en) Preparations containing amino acids are stored in halogen or in the nitrogen for use.
EA201890220A1 (ru) Вакцина против rsv
BR112014029966A2 (pt) proteínas de fator de crescimento de fibroblasto 21
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
BRPI0513819A (pt) inibidores de hsp90
CY1112185T1 (el) Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη
HRP20191965T1 (hr) Stabilizirani polipeptidi faktora rasta slični inzulinu
WO2007022193A3 (en) Process for the preparation of copolymer-1
BRPI0513857A (pt) inibidores de hsp90
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
BR112012011267A2 (pt) substâncias ativas poliméricas ou oligoméricas com efeito biocida, processos para a sua produção e composição compreendendo uma substância ativa polimérica ou oligomérica
RS51325B (sr) Polipeptidi koji imaju antimikrobno dejstvo i polinukleotidi koji ih kodiraju
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
WO2013021284A3 (en) Anti-il-6 vaccine composition
BRPI0519599A2 (pt) salicilamida n-substituÍda, bem como mÉtodo de preparaÇço, composiÇço farmacÊutica e uso da referida salicilamida n-substituÍda
JO3684B1 (ar) صور متبلرة من الملح ثنائي الصوديوم لحمض n-(5-كلورو ساليسلويل)-8-امينو كابريليك

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2208 DE 30/04/2013.